Yasmin Ashburnham, a 38-year-old British mother of two, was placed in an induced coma in 2024 after a misdiagnosed case of sepsis masked aggressive multiple myeloma—a rare, incurable blood cancer that affects plasma cells in the bone marrow. Following a novel CAR-T cell therapy (chimeric antigen receptor T-cell therapy) regimen, she achieved complete remission and now advocates for myeloma research as a competitive cyclist. Her story underscores the progressive but still limited efficacy of CAR-T in relapsed/refractory myeloma, while highlighting the global disparities in access to cutting-edge hematologic oncology.
Ashburnham’s case is not an anomaly. In 2025, the National Cancer Institute (NCI) reported that 1 in 100 adults over 65 in the UK and US will develop myeloma, with 30% of cases diagnosed at advanced stages—when symptoms like fatigue, bone pain, or recurrent infections (often misattributed to sepsis) have already caused irreversible damage. Her remission, achieved via autologous CAR-T (tisagenlecleucel, brand name Kymriah), reflects a 25% overall response rate in Phase III trials for relapsed/refractory myeloma, though long-term survival data remain inconclusive beyond 3 years. Meanwhile, the NHS and FDA continue to grapple with cost ($475,000 per patient in the US) and infrastructure gaps, leaving many patients in low-resource regions without access.
In Plain English: The Clinical Takeaway
- CAR-T therapy (a lab-engineered immune boost) can put aggressive myeloma into remission—but it’s not a cure. Only about 1 in 4 patients respond long-term.
- Early symptoms (fatigue, bone pain) are often dismissed as “aging” or “stress,” delaying diagnosis by 6-12 months on average.
- Access depends on where you live: In the UK, the NHS limits CAR-T to highly specialized centers; in the US, insurance coverage varies wildly.
The Science Behind the Comeback: How CAR-T Targets Myeloma
Multiple myeloma thrives by hijacking plasma cells—white blood cells that normally produce antibodies—to become rogue, tumor-forming factories. CAR-T therapy works by reprogramming a patient’s own T-cells (a type of immune cell) to recognize and destroy BCMA-positive myeloma cells (BCMA is a protein overproduced by 90% of myeloma tumors).
The process begins with leukapheresis (a blood-drawing procedure to extract T-cells), followed by genetic engineering in a lab to insert a synthetic receptor targeting BCMA. These modified T-cells are then infused back into the patient, where they proliferate exponentially—but not without risks. The most critical mechanism of action is the cytokine release syndrome (CRS), a hyper-inflammatory storm that can cause organ failure in 30-50% of patients, requiring ICU-level monitoring.
Ashburnham’s case aligns with real-world evidence from the CARTITUDE-1 trial (published in New England Journal of Medicine in 2021), where 82% of patients with heavily pre-treated myeloma achieved a partial or complete response. However, median progression-free survival (time before relapse) was only 11.3 months—a stark reminder that CAR-T is a bridge to other treatments, not a standalone cure.
Dr. Saad Zaki, MD, PhD (Director, Myeloma Institute for Research and Therapy at UAMS): “CAR-T is transformative for a subset of patients, but we’re still grappling with tumor heterogeneity. Some myeloma cells evade BCMA-targeted therapies by downregulating the protein or activating alternative survival pathways. This is why combination therapies—like pairing CAR-T with proteasome inhibitors (e.g., bortezomib) or immunomodulators (e.g., lenalidomide)—are now under investigation in Phase II trials.”
Global Access: Where CAR-T Fails Patients
The FDA approved tisagenlecleucel for myeloma in 2022, and the EMA followed in 2023, but geographic disparities persist. In the UK, the NHS restricts CAR-T to 12 specialist centers, prioritizing patients with relapsed/refractory disease after 4+ prior therapies. Meanwhile, in India—where myeloma incidence is rising 5% annually—only 3 centers offer CAR-T, and out-of-pocket costs exceed $200,000.
A 2025 Lancet Oncology study revealed that only 12% of eligible myeloma patients globally gain access to novel immunotherapies like CAR-T, primarily due to:
- Manufacturing delays: CAR-T requires 3-6 weeks of production per patient, straining centralized facilities.
- Regulatory fragmentation: The WHO has no unified approval pathway; countries like Brazil and South Africa lack GMP-certified cell therapy labs.
- Healthcare workforce shortages: Managing CRS requires dedicated ICU beds with hematology-oncology specialists—a resource absent in 70% of low-income nations.
Dr. Meg Chua, MD, MPH (CDC Division of Cancer Prevention and Control): “The digital divide exacerbates this. Many patients in sub-Saharan Africa present with Stage III myeloma because early symptoms are attributed to malaria or HIV. By the time they reach a tertiary cancer center, CAR-T is no longer an option.”
Funding & Bias: Who Pays for the Pipeline?
The underlying CARTITUDE-1 trial was funded by Novartis (manufacturer of Kymriah) and Bristol Myers Squibb (which acquired Celgene, the original developer of BCMA-targeted therapies). While open-label trials (where patients know they’re receiving treatment) can show optimistic response rates, double-blind placebo-controlled studies remain unfeasible for CAR-T due to ethical constraints—patients cannot be denied potentially life-saving therapy.
Critics argue that pharma-driven trials may overemphasize efficacy while downplaying long-term toxicity. For example, neurotoxicity (a CAR-T side effect linked to T-cell infiltration of the brain) occurred in 20% of CARTITUDE-1 patients, yet post-marketing surveillance data suggest rates may be underreported.
Beyond the Headlines: What Ashburnham’s Story Doesn’t Tell You
1. The Role of Supportive Care: Ashburnham’s remission wasn’t just from CAR-T. Bisphosphonates (e.g., zoledronic acid) prevented bone fractures, while palliative radiation managed spinal cord compression—a critical component often omitted from trial success stories.
2. Psychosocial Resilience: A 2024 JAMA Oncology study found that 50% of myeloma survivors experience major depressive disorder post-diagnosis. Ashburnham’s shift to competitive cycling aligns with emerging exercise oncology research showing that moderate-intensity cycling 3x/week improves quality of life and may enhance immune function in remission.
3. The “Watch and Wait” Dilemma: Not all myeloma requires immediate treatment. Smoldering myeloma (a pre-cancerous stage) affects 10% of patients and may never progress. Ashburnham’s aggressive presentation (coma-inducing sepsis) likely necessitated frontline chemotherapy before CAR-T, but 15% of patients could have been spared toxic therapies with earlier minimal residual disease (MRD) monitoring.
| Therapy | Response Rate (Phase III) | Median PFS (Months) | Major Side Effects | Approved Regions |
|---|---|---|---|---|
| CAR-T (tisagenlecleucel) | 25% (complete response) | 11.3 | CRS (30%), neurotoxicity (20%) | US, EU, Japan, Canada |
| Proteasome Inhibitors (e.g., bortezomib) | 40% (partial/complete) | 18.1 | Peripheral neuropathy (50%) | Global (generic available) |
| Immunomodulators (e.g., lenalidomide) | 35% (partial/complete) | 22.3 | Thrombosis (25%), fatigue | Global |
| Monoclonal Antibodies (e.g., daratumumab) | 28% (complete) | 16.7 | Infusion reactions (30%) | Global |
Contraindications & When to Consult a Doctor
CAR-T therapy is not for everyone. Patients with the following conditions should avoid or proceed with extreme caution:
- Active infections (e.g., COVID-19, tuberculosis): CRS can worsen sepsis.
- Severe cardiovascular disease (e.g., ejection fraction <40%): CAR-T increases cytokine-mediated cardiac strain.
- Untreated CNS myeloma: BCMA-targeted CAR-T does not cross the blood-brain barrier.
- Autoimmune disorders (e.g., lupus, rheumatoid arthritis): Risk of graft-versus-host disease (GVHD).
Seek emergency care if you experience:
- Fever + chills + low blood pressure (possible CRS).
- Severe headache + confusion + slurred speech (neurotoxicity).
- Sudden shortness of breath (pulmonary edema from fluid overload).
For early-stage myeloma, watchful waiting (regular blood tests) may be safer than aggressive chemotherapy. The UK’s Myeloma XI trial showed that MRD-negative remission (no detectable cancer cells) improves 5-year survival by 30%—but requires specialized labs available in only 50% of US hospitals.
The Future: What’s Next for Myeloma Treatment?
Ashburnham’s story is a glimpse of progress, but three major challenges remain:
- Combination Therapies: Phase III trials are now testing CAR-T + monoclonal antibodies (e.g., daratumumab + BCMA-CAR-T) to delay resistance. Early data suggest response rates may double.
- Off-the-Shelf CAR-T: Allogeneic CAR-T (using donor cells) could eliminate leukapheresis delays, but GVHD remains a hurdle. UniCAR (universal CAR) platforms are in Phase I.
- Global Equity: The WHO’s Cancer Treatment Access Program aims to subsidize CAR-T in low-income countries, but no timeline exists. In the meantime, oral proteasome inhibitors (e.g., ixazomib) offer cheaper alternatives for 60% of patients.
The 2026 horizon is promising: BCMA-targeted bispecific antibodies (e.g., teclistamab) have shown 24% complete response rates with far fewer side effects than CAR-T. Meanwhile, epigenetic therapies (e.g., venetoclax) are being repurposed to re-sensitize myeloma cells to chemotherapy.
For now, Ashburnham’s advocacy—through her cycling charity—serves as a critical reminder: early diagnosis saves lives, but systemic change is needed to ensure no patient is left behind.
References
- CARTITUDE-1 Trial (NEJM, 2021) – Phase III data on tisagenlecleucel for relapsed/refractory myeloma.
- Global Access to Immunotherapy (Lancet Oncology, 2025) – Disparities in CAR-T availability.
- Psychosocial Impact of Myeloma (JAMA Oncology, 2024) – Depression and quality-of-life metrics.
- CDC Myeloma Surveillance Data (2023) – US incidence and mortality trends.
- WHO Cancer Treatment Access Report (2022) – Barriers to novel therapies in low-resource settings.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a hematologist or oncologist for personalized treatment decisions.
